Latest Histone deacetylase Stories
Today, during the 87th General Session of the International Association for Dental Research, convening at the Miami Beach Convention Center, a group of scientists from Nihon University
SINGAPORE, Dec. 1 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of a Phase 1/2 clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with chronic idiopathic myelofibrosis (CIMF).
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced today the presentation of a poster highlighting preclinical synergy of Cyclacel's sapacitabine when given in combination with histone deacetylating agents (HDAC) valproate and vorinostat.
MethylGene, a clinical stage biopharmaceutical company, has announced that Health Canada has approved the company's clinical trial application for MGCD290, a fungal Hos2 histone deacetylase inhibitor to be used in combination with azoles for the treatment of fungal infections.
WALTHAM, Mass., Sept. 16 /PRNewswire-FirstCall/ -- Repligen Corporation today reported publication of a preclinical study demonstrating that a novel histone deacetylase (HDAC) inhibitor improved disease symptoms in a transgenic animal model of Huntington's disease.
U.S. chemists synthesize promising anti-cancer product WASHINGTON, Aug.
U.S. scientists say they've found a marine compound that inhibits cancer cell growth in lab tests and that might lead to new anti-cancer drugs. University of Florida College of Pharmacy researchers said the patented compound, called largazole, is derived from cyanobacteria that grow on coral reefs.
Researchers at The Children's Hospital of Philadelphia have manipulated cell activity that occurs during the interruption of blood flow to strongly protect heart tissue in animal studies.
ValiRx plc (AIM:VAL, 'ValiRx'), the cancer therapeutics and diagnostics company, has announced promising in vivo results for its lead molecule VAL 101 which uses its gene silencing technology GeneICE(TM) in preclinical xenograph models of pancreatic cancer.
Gloucester Pharmaceuticals has reported positive data from a Phase II trial of romidepsin, a novel, cyclic peptide, pan-HDAC inhibitor under investigation for hematologic malignancies.